In a cohort study comparing high-risk definitions for smoldering multiple myeloma (#SMM), the AQUILA trial criteria was assessed against the 2/20/20 risk model.
The AQUILA criteria classified approximately 3 times more individuals as high-risk versus the 2/20/20 model, but included a substantial group with lower progression risk.
The 2/20/20 model more precisely identified a smaller group of individuals with higher risk of progression, supporting its use to target early intervention for those most likely to benefit.
This cohort study compares the AQUILA trial inclusion criteria and the 2/20/20 risk stratification model definitions for identifying individuals with smoldering multiple myeloma at high risk of progression.








